BioCentury | Nov 24, 2020
Product Development

Less is more: If AZ’s low-dose COVID-19 vaccine regimen works better, more people will benefit

...its sublicensing partners who are manufacturing for rest...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...Greater China and then on to the rest...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

...and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest...
BioCentury | Nov 12, 2020
Product Development

COVID mAb data from Lilly, AbCellera suggest monotherapy may soon be superseded by Lilly’s combo

Whether the spike-targeting mAb bamlanivimab from Eli Lilly and AbCellera will have a substantial impact on the COVID-19 pandemic boils down to two factors: the strength of its efficacy and its availability....
BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...ask panelists to vote on whether Biogen should run another trial, and Dunn spent the rest...
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

...in milestones. According to CStone’s website, sugemalimab has reached pivotal trials in China, while in the rest...
...time frame to each other.”CS1003 is in clinical proof-of-concept testing in both China and the rest...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech’s fund-raising equation with some clear advantages over traditional IPOs for the right type of company. But...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

...is that U.S. citizens should subsidize the rest...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...patients who converted from HER2-negative, hormone receptor-positive to triple negative responded as well as the rest...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...health workers in China. And obviously the rest...
Items per page:
1 - 10 of 1956